Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

Steven M. Trifilio*, Alfred W. Rademaker, Diane Newman, Katherine Coyle, Katrin Carlson-Leuer, Jayesh Mehta, Jessica Altman, Olga Frankfurt, Martin S. Tallman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.

Original languageEnglish (US)
Pages (from-to)394-396
Number of pages3
JournalLeukemia Research
Volume36
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Etoposide
  • Mitoxantrone

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this